ESMO 2021 | ctDNA assay for detection of recurrent disease in patients with early-stage breast cancer

Wolfgang Janni, MD, PhD, University of Ulm, Ulm, Germany, discusses a circulating tumor DNA (ctDNA) assay used to detect recurrent disease in early-stage breast cancer. By creating a mutation library at the time of diagnosis, it is possible to follow-up on the mutational changes occurring during the course of the disease. Prof. Janni explains that the assay had a sensitivity of 92% for detection of ctDNA and will soon be further examined in a large study. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.